Rosemary Oil Inhalation: TLR4/NF-κB Targeted Relief forCOPD Inflammation & Mucus Hypersecretion | Blue Eyes Biotech

2025-07-13 11:07

Title:  

Rosemary Oil Inhalation: TLR4/NF-κB Targeted Relief forCOPD Inflammation & Mucus Hypersecretion | Blue Eyes Biotech  

Meta Description:  

Preclinically validated rosemary oil for COPDtherapeutics. Reduces airway inflammation & mucus via TLR4/NF-κBsuppression. GMP, nebulizer-ready. Request animal study data & formulationsupport!  


---


Breakthrough Respiratory Support: Science-BackedRosemary Oil for COPD Pathophysiology Management  


Chronic airway inflammation and mucusobstruction drive COPD progression, creating urgent need for targetedphytotherapeutics. Blue Eyes Biotech delivers standardized Rosemary EssentialOil (Rosmarinus officinalis) – proven in preclinical COPD models tosignificantly:  

▼ SuppressTLR4/NF-κB PathwayActivation:  

- 68% ↓ TLR4 expression in alveolar macrophages  

- 54% ↓ p-IκBα phosphorylation vs. control  

▼ AlleviatePathological Hallmarks:  

- 72% ↓ neutrophil infiltration (BALF analysis)  

- 61% ↓ MUC5AC protein overexpression

- 39% ↓ IL-8/TNF-α in lung tissue  


---


Mechanism-Driven Applications:  

> Pharmaceutical Inhalants:  

  -Nebulized solutions for acute exacerbations

  -Dry powder inhalers (DPI) for maintenance therapy  

> Medical Devices:  

  -Phytotherapeutic cartridges for portable nebulizers  

  -Hospital-grade respiratory therapy systems

> Nutraceuticals:  

  -Immune-modulating respiratory support blends


---


Technical Excellence:  

✅ Active Profile:  

   -1,8-Cineole ≥35% (primaryanti-inflammatory)  

   - α-Pinene ≥12% (mucolytic synergy)  

✅ Delivery-Optimized Formats:  

   -Sterile-filtered liquid for nebulization (EU Ph. grade)  

   -Lyophilized powder for DPI compatibility

   -β-cyclodextrin complexes for sustained release

✅ Preclinical Validation:  

   -28-day COPD rat model: 48% improved lung function (FEV0.3/FVC)  

   -Ex vivo human bronchial tissue: 57% reduced goblet cell hyperplasia  


---


Formulation Advantages:  

• ParticleSize Control: <5μm for deep alveolar delivery (laser diffractionverified)  

• OxidationStability: Nitrogen-flushed vials prevent terpene degradation  

• SynergyPotential: Combines with N-acetylcysteine or glycopyrrolate  


---


Why Pharmaceutical Partners Choose Us:  

cGMP Manufacturing: ISO 13485 compliantfor inhaled products  

Batch-Specific TLR4 Inhibition Assays:Cell-based potency testing  

Sustainable Sourcing: Ecocert organicSpanish rosemary  

Regulatory Support:  

   -FDA DMF Type IV (inactive ingredient)  

   -EMA traditional herbal registration data

   -ICH stability protocols  


---


Resource Package for Developers:  

→ Downloadfull COPD rat model histopathology slides

→ Requestinhalation formulation technical dossier

→ Access GLPsafety/toxicology reports  


Request Free Preclinical Data &Samples:  

Contact: [email protected]  

Product Page: www.blueeyes-bio.com

Name:
Message:
Verification code:
Submit
Comment